Related Experiment Video
Updated: Jan 27, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
The Role of PD-L1 Testing in Advanced Genitourinary Malignancies
Andrew W Hahn1, Deepika Sirohi1, Neeraj Agarwal1
1Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Abstract:
In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression should not receive single-agent immune checkpoint inhibition treatment. By contrast, PD-L1 should not be tested in metastatic renal cell carcinoma and platinum-refractory mUC.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...
Anatomy of the Genitourinary System II: Bladder and Urethra
Anatomy of the Genitourinary System I: Kidneys and Ureters
Extraction: Advanced Methods